# Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD

> **NCT04500847** · PHASE1 · RECRUITING · sponsor: **Butler Hospital** · enrollment: 35 (estimated)

## Conditions studied

- Alzheimer Disease, Early Onset
- Mild Cognitive Impairment
- Moderate Dementia

## Interventions

- **DRUG:** Emtriva Capsule
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04500847
- **Lead sponsor:** Butler Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-17
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-03-31
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2025-05-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04500847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04500847, "Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04500847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*